QUESTION: Do you have any research/ case studies on using hbot in oncology? I’m having a tough time with understanding why it is being done, have you written about it and i missed it? It possibly makes sense after patient is given an iv but i have had requests from patients and seen orders for random hbot as high as 1.6/1.7 ATA with no ivs…
ANSWER: On the surface (HBOT-CA) is confusing. There is absolutely NO good resource as those of us doing it clinically are finding the actual clinical truths of its effect as we go so older data is really next to worthless or just plain confusing. I am writing on it now and collecting data. I’m also the first clinician to present on the results and science behind HBOT in oncology at the HBOT meeting in November. Bottom line, for many tumor promotor factors the HBOT is one way to quell the promotor. You have to do many other things to synergize (if they don’t it isn’t as good) but it is a critical therapy in many Onc settings. The data and presentation for the HBOT society will be made into a CME webinar as well and be part of the new Oncology Fellowship.